These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

141 related items for PubMed ID: 10803836

  • 1. Failure pattern implications following external beam irradiation of prostate cancer: long-term follow-up and indications of cure.
    Hanlon AL, Hanks GE.
    Cancer J; 2000 Apr; 6 Suppl 2():S193-7. PubMed ID: 10803836
    [Abstract] [Full Text] [Related]

  • 2. Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.
    Wong WW, Schild SE, Vora SA, Halyard MY.
    Int J Radiat Oncol Biol Phys; 2004 Sep 01; 60(1):24-9. PubMed ID: 15337536
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):795-9. PubMed ID: 15925452
    [Abstract] [Full Text] [Related]

  • 5. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy.
    Cheung R, Tucker SL, Lee AK, de Crevoisier R, Dong L, Kamat A, Pisters L, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Mar 15; 61(4):993-1002. PubMed ID: 15752878
    [Abstract] [Full Text] [Related]

  • 6. Candidates for prostate radioactive seed implantation treated by external beam radiotherapy.
    Seung SK, Kroll S, Wilder RB, Posner MD, Roach M.
    Cancer J Sci Am; 1998 Mar 15; 4(3):168-74. PubMed ID: 9612598
    [Abstract] [Full Text] [Related]

  • 7. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C, Kestin LL, Weed DW, Krauss D, Vicini FA, Martinez AA.
    Int J Radiat Oncol Biol Phys; 2005 Mar 01; 61(3):714-24. PubMed ID: 15708249
    [Abstract] [Full Text] [Related]

  • 8. What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?
    Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg DF, Pollack A.
    Int J Radiat Oncol Biol Phys; 2005 Mar 15; 61(4):1003-10. PubMed ID: 15752879
    [Abstract] [Full Text] [Related]

  • 9. Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy.
    Cheung R, Tucker SL, Lee AL, Dong L, Kamat A, Pisters L, Kuban DA.
    Int J Radiat Oncol Biol Phys; 2005 Jan 01; 61(1):14-9. PubMed ID: 15629589
    [Abstract] [Full Text] [Related]

  • 10. Conformal high dose rate iridium-192 boost brachytherapy in locally advanced prostate cancer: superior prostate-specific antigen response compared with external beam treatment.
    Stromberg JS, Martinez AA, Horwitz EM, Gustafson GS, Gonzalez JA, Spencer WF, Brabbins DS, Dmuchowski CF, Hollander JB, Vicini FA.
    Cancer J Sci Am; 1997 Jan 01; 3(6):346-52. PubMed ID: 9403047
    [Abstract] [Full Text] [Related]

  • 11. High-dose-rate intensity-modulated brachytherapy with external beam radiotherapy for prostate cancer: California endocurietherapy's 10-year results.
    Demanes DJ, Rodriguez RR, Schour L, Brandt D, Altieri G.
    Int J Radiat Oncol Biol Phys; 2005 Apr 01; 61(5):1306-16. PubMed ID: 15817332
    [Abstract] [Full Text] [Related]

  • 12. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB.
    Int J Radiat Oncol Biol Phys; 2004 Apr 01; 58(5):1520-9. PubMed ID: 15050332
    [Abstract] [Full Text] [Related]

  • 13. [Biochemical monitoring of prostate cancer treated exclusively by radiotherapy: prognostic value of pretreatment PSA, PSA nadir and PSA half-life].
    Chautard D, Cellier P, Dalifard I, Pabot du Chatelard P, Chaussis F, Vielle B, Soret JY, Passagot J, Courte C, Daver A.
    Prog Urol; 2002 Jun 01; 12(3):421-8. PubMed ID: 12189749
    [Abstract] [Full Text] [Related]

  • 14. Hazard rates of disease progression after external beam radiotherapy for clinically localized carcinoma of the prostate.
    Rosser CJ, Levy LB, Kuban DA, Chichakli R, Pollack A, Lee A, Pisters LL.
    J Urol; 2003 Jun 01; 169(6):2160-5. PubMed ID: 12771739
    [Abstract] [Full Text] [Related]

  • 15. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
    D'Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP.
    Cancer; 2002 Jul 15; 95(2):281-6. PubMed ID: 12124827
    [Abstract] [Full Text] [Related]

  • 16. Improved biochemical disease-free survival of men younger than 60 years with prostate cancer treated with high dose conformal external beam radiotherapy.
    Zelefsky MJ, Marion C, Fuks Z, Leibel SA.
    J Urol; 2003 Nov 15; 170(5):1828-32. PubMed ID: 14532785
    [Abstract] [Full Text] [Related]

  • 17. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA.
    J Urol; 2001 Sep 15; 166(3):876-81. PubMed ID: 11490237
    [Abstract] [Full Text] [Related]

  • 18. Long-term prostate cancer control using palladium-103 brachytherapy and external beam radiotherapy in patients with a high likelihood of extracapsular cancer extension.
    Dattoli M, Wallner K, True L, Cash J, Sorace R.
    Urology; 2007 Feb 15; 69(2):334-7. PubMed ID: 17320673
    [Abstract] [Full Text] [Related]

  • 19. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up.
    Ragde H, Korb LJ, Elgamal AA, Grado GL, Nadir BS.
    Cancer; 2000 Jul 01; 89(1):135-41. PubMed ID: 10897010
    [Abstract] [Full Text] [Related]

  • 20. Clinical results of combined treatment conformal high-dose-rate iridium-192 brachytherapy and external beam radiotherapy using staging lymphadenectomy for localized prostate cancer.
    Hiratsuka J, Jo Y, Yoshida K, Nagase N, Fujisawa M, Imajo Y.
    Int J Radiat Oncol Biol Phys; 2004 Jul 01; 59(3):684-90. PubMed ID: 15183471
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.